{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:08:23Z","timestamp":1785784103354,"version":"3.56.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015805","name":"Shenzhen Municipal Science and Technology Innovation Council","doi-asserted-by":"publisher","award":["KJZD20230923115214029"],"award-info":[{"award-number":["KJZD20230923115214029"]}],"id":[{"id":"10.13039\/501100015805","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Gastric cancer is one of the most diagnosed cancers and a major contributor to cancer-related death in China. Recent studies have demonstrated the failure of tumor mutational burden (TMB) in predictive accuracy. Here, we aimed to evaluate the prognostic value of tumor neoantigen burden (TNB) to predict the clinical outcome among patients undergoing gastric cancer resection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study performs whole exome and transcriptome sequencing of tumor tissues of 85 gastric cancer patients who underwent resection surgery. The prognostic value of TMB and TNB in Chinese gastric cancer patients were evaluated, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In contrast to TMB, TNB achieved significance in predicting overall survival at both early (a median follow-up period of 23.5 month) and late (a median follow-up period of 35.5 month) timepoints (p-value&amp;lt;0.05), particularly with expanding 2-year and 3-year restricted mean survival time (RMST). According to the comparative enrichment and protein-protein interaction analysis of TNB- and TMB-associated genes, we found the upregulated TNB-associated genes were significantly enriched in hormone and nutrient sensing cascades, whereas their counterparts were predominantly linked to cytoskeletal development. In addition, we also noticed an increased infiltration of neutrophils in TNB-High group (p-value=0.04).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>In summary, this study indicated that the prognosis of TNB-High patients was significantly better than their counterparts, which might be associated with impaired energy metabolism.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1722895","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T07:43:35Z","timestamp":1767599015000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Beyond tumor mutation burden: tumor neoantigen burden as a superior prognostic biomarker in resected gastric cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Tingting","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhida","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenglin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiya","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqing","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jncc.2022.02.002","article-title":"Cancer incidence and mortality in China, 2016","volume":"2","author":"Zheng","year":"2022","journal-title":"J Natl Cancer Center"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318760","article-title":"Meta-analysis of genome-wide association studies and functional assays decipher susceptibility genes for gastric cancer in Chinese populations","volume":"69","author":"Yan","year":"2020","journal-title":"Gut"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2018.03.01","article-title":"Incidence and mortality of stomach cancer in China, 2014","volume":"30","author":"Yang","year":"2018","journal-title":"Chin J Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(18)30127-X","article-title":"Changing cancer survival in China during 2003\u201315: a pooled analysis of 17 population-based cancer registries","volume":"6","author":"Zeng","year":"2018","journal-title":"Lancet Global Health"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-009-4251-y","article-title":"Investigation of the recurrence patterns of gastric cancer following a curative resection","volume":"41","author":"Deng","year":"2011","journal-title":"Surg Today"},{"key":"B6","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12957-016-1042-y","article-title":"The patterns and timing of recurrence after curative resection for gastric cancer in China","volume":"14","author":"Liu","year":"2016","journal-title":"World J Surg Onc"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2017.09.08","article-title":"Does histology really influence gastric cancer prognosis","volume":"8","author":"Luu","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000152019.14741.97","article-title":"Prediction of recurrence after radical surgery for gastric cancer: A scoring system obtained from a prospective multicenter study","volume":"241","author":"Marrelli","year":"2005","journal-title":"Ann Surg"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-011-1247-8","article-title":"Factors associated with recurrence within 2 years after curative surgery for gastric adenocarcinoma","volume":"35","author":"Chiang","year":"2011","journal-title":"World J Surg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000143245.28656.15","article-title":"Patterns of initial recurrence in completely resected gastric adenocarcinoma","volume":"240","author":"D\u2019Angelica","year":"2004","journal-title":"Ann Surg"},{"key":"B11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.20892\/j.issn.2095-3941.2024.0386","article-title":"Advances and challenges in gastric cancer testing: the role of biomarkers","volume":"22","author":"Sun","year":"2025","journal-title":"Cancer Biol Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.683419","article-title":"FDA-approved and emerging next generation predictive biomarkers for immune checkpoint inhibitors in cancer patients","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J immunotherapy Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1709968","article-title":"First FDA approval agnostic of cancer site \u2014 When a biomarker defines the indication","volume":"377","author":"Lemery","year":"2017","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4191","article-title":"Classification and characterization of microsatellite instability across 18 cancer types","volume":"22","author":"Hause","year":"2016","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"key":"B17","volume-title":"FDA approves pembrolizumab for adults and children with TMB-H solid tumors","year":"2020"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14046","article-title":"Neoantigen load as a prognostic and predictive marker for stage II\/III non-small cell lung cancer in Chinese patients","volume":"12","author":"Gong","year":"2021","journal-title":"Thorac Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/ng.806","article-title":"A framework for variation discovery and genotyping using next-generation DNA sequencing data","volume":"43","author":"DePristo","year":"2011","journal-title":"Nat Genet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13059-016-0893-4","article-title":"deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution","volume":"17","author":"Rosenthal","year":"2016","journal-title":"Genome Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkad347","article-title":"g:Profiler\u2014interoperable web service for functional enrichment analysis and gene identifier mapping (2023 update)","volume":"51","author":"Kolberg","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e0294236","DOI":"10.1371\/journal.pone.0294236","article-title":"SRplot: A free online platform for data visualization and graphing","volume":"18","author":"Tang","year":"2023","journal-title":"PloS One"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: A software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-011-0041-5","article-title":"Japanese classification of gastric carcinoma: 3rd English edition","volume":"14","year":"2011","journal-title":"Gastric Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1422640112","article-title":"Mutational landscape of gastric adenocarcinoma in Chinese: Implications for prognosis and therapy","volume":"112","author":"Chen","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2022.10.019","article-title":"Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer","volume":"51","author":"Cheng","year":"2023","journal-title":"J Advanced Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2022.02.004","article-title":"The neoantigen landscape of the coding and noncoding cancer genome space","volume":"24","author":"Lau","year":"2022","journal-title":"J Mol Diagnostics"},{"key":"B34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.5230\/jgc.2016.16.2.78","article-title":"Primary tumor resection and survival in patients with stage IV gastric cancer","volume":"16","author":"M\u00fcsri","year":"2016","journal-title":"J Gastric Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-015-0480-5","article-title":"The survival difference between gastric cancer patients from the UK and Japan remains after weighted propensity score analysis considering all background factors","volume":"19","author":"Yamada","year":"2016","journal-title":"Gastric Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.006","article-title":"TMB cut-offs fail to predict benefit of PD-1 blockade in gastroesophageal adenocarcinoma in KEYNOTE-061","volume":"32","author":"Foote","year":"2021","journal-title":"Ann Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.027","article-title":"Response to the letter to the Editor: TMB cut-offs fail to predict benefit of PD-1 blockade in gastroesophageal adenocarcinoma in KEYNOTE-061","volume":"32","author":"Shitara","year":"2021","journal-title":"Ann Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.689076","article-title":"Prognostic value of neoantigen load in immune checkpoint inhibitor therapy for cancer","volume":"12","author":"Zou","year":"2021","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-023-03278-3","article-title":"Energy metabolism: a new target for gastric cancer treatment","volume":"26","author":"Liu","year":"2023","journal-title":"Clin Transl Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1722895\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T07:43:37Z","timestamp":1767599017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1722895\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2025.1722895"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1722895","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"article-number":"1722895"}}